39 terminated. 39 Phase 2, 6 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 39 | Terminated 39 |
| Phase 1 | 6 | Terminated 6 |
| Phase 3 | 3 | Terminated 3 |
Follow Bronchiolitis: new trials by email Literature Review of Bronchiolitis trials Research Report on Bronchiolitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant Echocardiography Test, Ibrutinib - Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Terminated | Mayo Clinic | 2 | 2024-12-13 | 2026-05-22 |
| Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant Leflunomide tablet - Musculoskeletal Disease Other, GVHD, Chronic | Phase 2 | Terminated | Tata Memorial Centre | 1 | 2023-09-18 | 2025-09-10 |
| Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias fostamatinib - Immune Mediated Anemia, Immune Mediated Thrombocytopenia | Phase 2 | Terminated | National Heart, Lung, and Blood Institute (NHLBI) | 1 | 2023-03-10 | 2025-12-05 |
| Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant Ruxolitinib - Hematopoietic Stem Cell Transplant (HSCT), Bronchiolitis Obliterans (BO) | Phase 2 | Terminated | Children's Hospital Medical Center, Cincinnati | 7 | 2021-11-12 | 2026-04-07 |
| A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib itacitinib - Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans) | Phase 2 | Terminated | Incyte Corporation | 18 | 2021-03-10 | 2026-06-26 |
| Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD Itacitinib, Extracorporeal Photopheresis (ECP) - Chronic Graft-versus-host-disease | Phase 2 | Terminated | University of Utah | 3 | 2021-01-29 | 2024-01-22 |
| A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD) Itacitinib - Chronic Graft-versus-host-disease | Phase 2 | Terminated | SCRI Development Innovations, LLC | 15 | 2020-06-05 | 2024-11-06 |
| Anlotinib Treatment in Steroid Depenent/Refractory cGVHD Anlotinib - Chronic Graft-versus-host-disease | Phase 2 | Terminated | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 5 | 2020-04-10 | 2021-03-24 |
| A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4) Liposomal Cyclosporine A, Liposomal Placebo - Bronchiolitis Obliterans Syndrome (BOS), GVHD, Chronic | Phase 2 | Terminated | Zambon SpA | 6 | 2020-02-11 | 2023-10-03 |
| Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation Itacitinib - Bronchiolitis Obliterans Syndrome | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 23 | 2020-02-04 | 2025-10-20 |
| Ibrutinib and Rituxan for Chronic GVHD Rituximab, Ibrutinib - Graft Vs Host Disease | Phase 2 | Terminated | Northside Hospital, Inc. | 15 | 2019-12-16 | 2024-12-13 |
| Glasdegib for Chronic Graft-Versus-Host Disease Glasdegib - Chronic Graft Versus Host Disease, Fasciitis | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 15 | 2019-12-03 | 2024-10-29 |
| Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT Ibrutinib, Rituximab - Chronic Graft-versus-host-disease | Phase 1 / Phase 2 | Terminated | Dartmouth-Hitchcock Medical Center | 2 | 2019-04-11 | 2023-11-28 |
| GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease Itacitinib, Placebo, Methylprednisolone - Chronic Graft-versus-host Disease | Phase 2 / Phase 3 | Terminated | Incyte Corporation | 155 | 2019-01-17 | 2025-10-20 |
| Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy Belumosudil (KD025) - Chronic Graft-versus-host-disease | Phase 2 | Terminated | Kadmon, a Sanofi Company | 159 | 2018-10-11 | 2024-12-12 |
| Safety and Efficacy Study of SOM230 s.c. in Cluster Headache SOM230, Placebo - Cluster Headache - Episodic and Chronic | Phase 2 | Terminated | Novartis Pharmaceuticals | 28 | 2016-10-31 | 2021-01-05 |
| Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD Ponesimod - Chronic Graft Versus Host Disease | Phase 2 | Terminated | Actelion | 1 | 2016-09-29 | 2025-02-04 |
| Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD) ENTO, Placebo - Chronic Graft Versus Host Disease | Phase 2 | Terminated | Gilead Sciences | 66 | 2016-05-27 | 2018-12-26 |
| The Effectiveness of Nebulized Hypertonic Saline Solution for Acute Bronchiolitis nebulized 3% hypertonic solution - Bronchiolitis | Phase 2 | Terminated | University Medical Centre Ljubljana | 100 | 2015-12-01 | 2019-08-05 |
| Nebulized Adrenalin and Oral Betamethasone in Children With Bronchiolitis Attending Pediatric Emergencies. 0.9% saline solution, oral betamethasone placebo, adrenaline - Children, Bronchiolitis | Phase 2 / Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 195 | 2015-10-01 | 2017-09-12 |
Showing 20 of 39. Sign in to see all of them.
Bronchiolitis Obliterans Syndrome (32) · Bronchiolitis Obliterans (6) · Graft vs Host Disease (5) · Leukemia (2) · Breast Neoplasms (1) · Cluster Headache (1) · Cryptogenic Organizing Pneumonia (1) · Fasciitis (1) · Headache (1) · Hepatitis (1) · Hepatitis B (1) · Hepatitis B, Chronic (1) · Hepatitis C (1) · Immune System Diseases (1)
Bronchial Diseases (39) · Bronchitis (39) · Lung Diseases (39) · Lung Diseases, Obstructive (39) · Respiratory Tract Diseases (39) · Organizing Pneumonia (33) · Immune System Diseases (31) · Bronchiolitis Obliterans (30) · Graft vs Host Disease (27) · Infections (6) · Pathological Conditions, Signs and Symptoms (5) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Pathologic Processes (4)
itacitinib (5) · INCB039110 (4) · Rituximab (3) · ibrutinib (3) · Lenalidomide (2) · Prednisone (2) · Sirolimus (2) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · Acupuncture Therapy (1) · Alefacept (1) · Azithromycin (1) · BMS-833923 (1) · Betamethasone (1) · Bortezomib (1) · Budesonide (1)
Incyte Corporation (3) · M.D. Anderson Cancer Center (3) · Dana-Farber Cancer Institute (2) · Novartis Pharmaceuticals (2) · Actelion (1) · Alexion Pharmaceuticals, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Boston Scientific Corporation (1) · Bristol-Myers Squibb (1) · Children's Hospital Medical Center, Cincinnati (1) · Dartmouth-Hitchcock Medical Center (1) · FLUIDDA nv (1) · Fred Hutchinson Cancer Center (1) · Gilead Sciences (1) · Kadmon, a Sanofi Company (1)
United States (25) · Canada (7) · Germany (7) · Belgium (6) · France (5) · Spain (5) · United Kingdom (4) · Poland (3) · Austria (2) · China (2) · Finland (2) · Greece (2) · Israel (2) · Italy (2) · South Korea (2)
Amin Alousi, MD (1) · Catherine Lee, MD (1) · Corey Cutler, MD (1) · Daniel R Couriel (1) · Daniele D'Ambrosio, MD, PhD (1) · Elizabeth F Krakow, MD,CM, FRCPC (1) · Hyoung Jin Kang, MD, Ph.D (1) · Jamie Y Hur, D.O. (1) · Jayesh Mehta, MD (1) · John Kuruvilla (1) · John M Hill, MD (1)
PMID 23900970, PMID 24995515, PMID 25389139, PMID 26416925, PMID 34265047, PMID 35781099, PMID 37698881, PMID 38485149, PMID 40311075
2015 (2), 2019 (2), 2008 (1), 2018 (1), P30CA042014 (1)